Asia Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size & Outlook, 2026-2034

Asia Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Insights

According to Reed Intelligence analysis, the Asia Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market size stood at USD 323.06 Million in 2025 and is forecasted to reach USD 673.12 Million by 2034.
The market is projected to grow at a CAGR of 8.49% between 2026 and 2034.
By segment, Corticosteroids was the leading Drug Class in terms of market size in 2025.
Corticosteroids is expected to be the most lucrative Drug Class segment, exhibiting the fastest growth throughout the forecast period.

Other Key Findings

Asia Pacific held 22.28% share of the global Eosinophilic Granulomatosis with Polyangiitis Treatment Market size in 2025.
United States is expected to remain the largest contributor to the global market size by 2034.
By 2034, South Korea is anticipated to record the highest growth in Asia Pacific, with the market size expected to reach USD 34.79 Million.

Report Summary

Report Scope	Details
Base Year for Study	2025
Study Period	2022-2034
Historical Period	2022-2024
Forecast Period	2026-2034
Market Size In 2025	USD 323.06 Million
Market Size In 2034	USD 673.12 Million
Largest segment	Corticosteroids
Units	Revenue in USD Million
CAGR	8.49% (2026-2034)
Segmnetation Covered
Asia Pacific	China India Japan South Korea Taiwan Australia Singapore South East Asia
Drug Class	Corticosteroids Immunosuppressants Biologics
Route of Administration	Oral Injectable
End-Use	Hospitals Specialty Clinics Others
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Asia Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Country 2026-2034 (USD Million)

Asia Pacific	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
China	XX.x	XX.x	XX.x	122.89	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
India	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Japan	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
South Korea	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Taiwan	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Australia	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Singapore	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
South East Asia	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Asia Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Drug Class 2026-2034 (USD Million)

Drug Class	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Corticosteroids	XX.x	XX.x	XX.x	173.06	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Immunosuppressants	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Biologics	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Asia Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market Route of Administration 2026-2034 (USD Million)

Route of Administration	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Oral	XX.x	XX.x	XX.x	180.01	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Injectable	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Asia Pacific Eosinophilic Granulomatosis with Polyangiitis Treatment Market End-Use 2026-2034 (USD Million)

End-Use	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Hospitals	XX.x	XX.x	XX.x	176.84	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Specialty Clinics	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Others	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Author :

Reed Intelligence Research Team

The Reed Intelligence Research Team brings together over 15+ years of collective experience in market research, data analytics, and strategic consulting. Comprising seasoned analysts, economists, and industry specialists, the team delivers precise, data-driven insights across sectors including technology, healthcare, energy, manufacturing, and consumer goods. By combining domain expertise with modern analytical tools, they ensure each report meets the highest standards of accuracy and relevance.